+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 80Years
All Genders
ID06736860

Early and precise use of Tranexamic Acid guided by blood clot monitoring in adults with traumatic bleeding aged 18 to 80

Led by Nanfang Hospital, Southern Medical University · Updated on 2024-12-17

580

Participants Needed

1

Research Sites

61 weeks

Total Duration

AI-Summary

What This Trial Is About

Trauma is a major global health issue and the leading cause of death in people under 40 years old. This research evaluates the use of tranexamic acid TXA in trauma patients to reduce death rates by comparing a standard treatment method with a new approach guided by real-time blood clot monitoring using thromboelastography TEG. The study aims to improve the timing and precision of TXA use to lower mortality and thromboembolism risks in trauma patients. Participants receive an initial 1 gram dose of TXA intravenously within 3 hours of injury. One group then continues with a continuous 1 gram infusion over 8 hours the 11 regimen. The other group undergoes TEG testing to decide if additional TXA doses are needed up to three doses total, called the 1X regimen. TEG helps assess the bloods clotting and breakdown status to guide treatment more precisely. Throughout the study, participants are closely monitored for survival over 30 days, with additional tracking of blood transfusion needs, organ failure, and clotting events during their hospital stay. The study includes laboratory tests and TEG assessments to guide treatment decisions. The total participation timeline varies, with key outcomes measured up to a week in hospital and survival followed for 30 days.

CONDITIONS

Brief Title

Tranexamic Acid in Patients With Traumatic Bleeding Based on Dynamic Monitoring of Thromboelastography

Research Team

X

Xu Li, doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here